As­traZeneca-Alex­ion merg­er slides through FTC re­view af­ter sup­posed M&A crack­down pos­es no bar­ri­ers

The As­traZeneca-Alex­ion megamerg­er re­ceived a good sign Fri­day, de­spite warn­ing signs of the tides turn­ing against large M&A phar­ma deals.

US reg­u­la­tors at the FTC have cleared the ac­qui­si­tion for ap­proval, As­traZeneca an­nounced, all but sign­ing off on the deal to go through once it of­fi­cial­ly clos­es in the third quar­ter. As­traZeneca orig­i­nal­ly said it was plan­ning to buy out Alex­ion back in De­cem­ber for $39 bil­lion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN